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A commentary on
Major chromosomal breakpoint inter-
vals in breast cancer co-localize with
differentially methylated regions
by Tang MH, Varadan V, Kamalakaran S,
Zhang MQ, Dimitrova N, Hicks J. (2012).
Front Oncol 2:197. doi:10.3389/ fonc.2012.
00197
There has been a tremendous effort in sys-
tems biology to integrate multi-modal data
in the hope to uncover and, ideally, provide
a mechanistic explanation for the inter-
connectedness of the many features and
aberrations of cancer genomes. A recent
study authored by Tang and co-workers
(1), which appeared in Frontiers in Cancer
Genomics, provides an interesting example
of this approach. It has now been “democ-
ratically” elected, based on the number of
times that it has been accessed, to target the
broader audience of Frontiers of Oncology.
In their work, Tang and colleagues use
an interesting strategy to integrate DNA
methylation and DNA copy number data
from a curated set of 119 breast cancer
samples leading to their central observa-
tion of a significant spatial association
between differentially methylated regions
and chromosomal breakpoints. Almost
half (93) of 217 regions identified as differ-
entially methylated by their in-house DNA
methylation platform (MOMA) (2) were
found to be located within 1 Mb of DNA
breakpoint hot-spots, as assayed by their
copy-number ROMA (3) platform for the
same sample set. This observation of what
they term Breakpoint Enriched Differen-
tially Methylated Regions (BEDMRs) may
be interpreted as indicative of a causal rela-
tion, whether direct or indirect, between
DNA breaks and methylation. Such an
association between hypomethylation and
genomic instability has long been pro-
posed (4) and an interesting mechanistic
explanation has recently been offered
by De and Michor (5). They observed
that DNA copy-number aberrations are
more likely to occur downstream of G4
quadruplex sequence motifs that contain
hypo-methylated CpG di-nucleotides. The
DNA molecule can locally, in the vicinity of
such motifs, assume an alternate, non-B-
form secondary structure, which can be an
obstacle to replication forks (6) resulting in
an increased chance of replication errors.
The association between G4 quadruplexes
and chromosomal aberrations may not
hold in every case, however, as evidenced
by Eriksson and colleagues (7) who report
that this relationship exists in only some
of the focal amplifications that they have
analyzed.
Any model postulating a causal rela-
tionship between DNA breaks and aber-
rant methylation ultimately requires that
both phenomena interact within the same
cell. While the analysis performed by Tang
and colleagues is compatible with this
assumption, their strategy with its focus
on “hot-spots” of DNA breaks and differ-
ential DNA methylation does not, neces-
sarily, imply actual co-localization within
any given cell. Also compatible with their
analysis are models in which both phe-
nomena are entirely unrelated on the level
of individual events. In this case, the co-
localization across the set of cancer samples
could be the result of other mechanisms,
such as selection during the clonal can-
cer evolution (8). The theoretical under-
pinning of this hypothesis is that both
processes, independent of one another,
contribute to dysregulation of gene expres-
sion in cancer. Copy number alterations
are present in most cancers, frequently tar-
geting cancer related genes (9) and dis-
play cancer subtype specific patterns that
have been used for prognosis prediction,
molecular sub-classification (10) and can
even be used to develop tumor progres-
sion models (11). Similarly, DNA methy-
lation, an important epigenetic regulator
during normal cell development (12) and
is altered in diseased cellular states (13).
Patterns of aberrant methylation are a dis-
tinguishing feature of many cancer cells (4,
14) again leading to applications in prog-
nosis prediction, classification, and diag-
nosis (15, 16). In their paper, Tang and
co-workers investigate the tumor “clonal
evolution” aspect by analyzing the gene
content proximal to the BEDMRs. They
find several cancer biology relevant genes,
such as AKT1, ARNT, and PMS2 and their
literature analysis finds that 57% of the
BEDMRs overlap with at least one gene that
has more than three literature references
related to cancer. Unfortunately, while this
analysis is intriguing, the authors find that
their results do not unequivocally prove
the “tumor evolution” hypothesis, because
the statistics do not quite reach the thresh-
old of significance owing, likely, to their
relatively small dataset of a heterogeneous
disease – breast cancer.
Without overwhelming evidence in
favor of a selection of cancer genes dur-
ing clonal evolution, an alternative is
that certain structural genomic elements
might be particularly susceptible to both
DNA breaks and aberrant methylation.
The increased likelihood of recombination
close to Alu and other genomic repet-
itive elements has been associated with
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an increased propensity for DNA breaks
(17). At the same time, such repetitive ele-
ments are often GC rich, increasing the
opportunity for differential methylation.
In their study, Tang and colleagues report a
statistically significant distance association
between BEDMRs and Alu repeats within
3 Mb. Some 33 (35%) BEDMRs are located
within 3 Mb of an Alu element. The major-
ity of these BEDMRs (24/33) are hypo-
methylated. These BEDMRs encompass a
major histone cluster as well as a number
of oncogenes.
The work by Tang et al. also looks
at other facets of BEDMR biology.
The authors’ analysis strongly hints that
BEDMRs can be used to classify breast
cancer tumors along the lines of gene
expression-based subtypes. For instance,
the authors identified 58 BEDMRs that are
unique to basal-like samples. This obser-
vation agrees well with previous findings
showing that expression-based breast can-
cer subtypes are clearly evident in DNA
methylation (15) and copy-number (18)
data. The authors suspect that a larger
dataset is required to harness the power of
BEDMRs to stratify breast cancer subtypes
at a finer detail.
Going beyond the work presented by
Tang and co-workers, expression analy-
sis of genes located close to or within
BEDMRs, which would be particularly sen-
sitive to both methylation and copy num-
ber changes, could provide further evi-
dence for selective pressure during cancer
development shaping the spatial associa-
tion in their target genes. If this is indeed
the case, BEDMRs could be a stronger indi-
cator for “interesting” genes and potential
therapeutic targets than each signal indi-
vidually. The strength, or probably more
aptly “relative weakness,” of the associa-
tion between BEDMRs and cancer related
genes, however, suggests that the sample set
size must be very large. In Tang’s work, the
p-value barely reached the frequently used
significance level of p< 0.05, and this only
after “tuning” thresholds. In order to be
successful, a study aiming to utilize a sig-
nal as weak as reported here would there-
fore have to involve a much larger number
of samples, at least one order of magni-
tude or more. An extension of the analy-
sis involving miRNA could be beneficial.
A recent study examined the effect of DNA
methylation and copy number alterations
on the dysregulation miRNA expression in
breast cancer, identifying 70 such miRNAs
(19). Though Aure et al. used a different
platform to assay DNA methylation and
copy-number status, both they and Tang
et al. relied, at least in part, on the same
sample cohort (20).
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